Table 1.
Newcastle-Ottawa score for included cross-sectional studies
| Study | Representativeness of the sample | Sample size | Non-respondents | Ascertainment of the exposure | Comparability of subjects in different outcome groups | Assessment of the outcome | Statistical test is appropriate | Total score | Funding source |
| Araujo29 | 1 | 0 | 0 | 1 | 0 | NA | 1 | 3 | No description |
| Barandarian40 | 1 | 0 | 0 | 0 | 0 | NA | 1 | 2 | No description |
| Bekfani41 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 4 | No description |
| Kasner19 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 4 | Supported by the EC, FP7-Health-2010, MEDIA (261409) |
| Lainscak42 | 1 | 0 | 0 | 1 | 0 | NA | 1 | 4 | No description |
| Nieto Sandoval28 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | No description |
| Nunez22 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | Sociedad Española de Cardiología |
| Orynchak23 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | No description |
| Yeo43 | 1 | 0 | 0 | 1 | 0 | NA | 1 | 4 | Vifor Pharma |
| Yeo24 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 4 | No description |
NA, not available.